We are live on ! Find out more
CSCI

COSCIENS Biopharma Inc. Common Stock

Delisted

CSCI was delisted on the 3rd of September, 2025.

15 hedge funds and large institutions have $77K invested in COSCIENS Biopharma Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more capital invested

Capital invested by funds: $56.9K → $77K (+$20.2K)

0.2% more ownership

Funds ownership: 0.67%0.87% (+0.2%)

0% more funds holding

Funds holding: 1515 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
15
Holders Change
Holders Change %
0%
% of All Funds
0.2%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
2
Reduced
4
Closed
2
Calls
Puts
Net Calls
Net Calls Change

CSCI Hedge Fund Activity: Q1 2025 in Review

15 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q1 2025, worth a combined $77K — up 35% from $56.9K a quarter earlier.

Fund positioning in CSCI was balanced in Q1 2025: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 4 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $35.1K. The largest seller was National Bank of Canada, cutting an estimated $14.1K.

  • 15 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q1 2025, unchanged from Q4 2024.
  • Funds reported $77K of COSCIENS Biopharma Inc. Common Stock stock for Q1 2025, up 35% quarter-over-quarter.
  • 2 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q1 2025 and 2 closed out, a net change of 0 holders.
  • The largest COSCIENS Biopharma Inc. Common Stock buyer in Q1 2025 was Susquehanna International Group, an estimated $35.1K added.
  • The largest COSCIENS Biopharma Inc. Common Stock seller in Q1 2025 was National Bank of Canada, an estimated $14.1K sold.

Based on aggregated 13F filings for Q1 2025.